Navigation Links
Actonel Treats Hip Fractures In A Better Way Than Alendronate

New study shows that osteoporosis patients treated with Actonel are more likely to sustain when compared to alendronate. //These results were published today in the peer-reviewed journal Osteoporosis International after collecting data from 33,000 women with osteoporosis.

The study of 33,000 postmenopausal women showed that among patients newly prescribed one of the two most popular osteoporosis treatments, patients taking Actonel? (risedronate sodium) were approximately half as likely to sustain a hip fracture as those taking alendronate in the first year of treatment. 'The rapid onset of fracture reduction observed for risedronate in this study is consistent with results from randomised clinical trials of risedronate,' says Professor Pierre Delmas, study author, Universite Claude Bernard, Lyon.

'Earlier fracture protection means that fewer patients will suffer the devastating consequences of an osteoporotic fracture, helping to both preserve patients' quality of life and to reduce the economic burden of healthcare.'

The REAL (RisedronatE, ALendronate) retrospective cohort study included 33,830 women newly treated with once-weekly doses of either Actonel or alendronate in 'real-life' clinical practice. Results showed that at six months patients on Actonel had a 46% (p=0.02) lower incidence of hip fractures compared to patients on alendronate. At 12 months similar results were seen, with Actonel resulting in a 43% (p=0.01) greater reduction in risk of hip fracture versus alendronate. The two treatments were not compared on the basis of side effects in this study.

This study adds to the body of evidence from randomised controlled trials demonstrating that Actonel exerts an early onset of fracture protection, seen as early as six months for clinical vertebral fracture and nonvertebral fractures. No other bisphosphonate treatments for osteoporosis have been shown in clinical trials to reduce clinical fractures this early for pat ients. However, data are limited that compare therapies directly in the same study on the basis of fracture reduction - the clinically important endpoint in osteoporosis treatment.

'In the osteoporosis field it is unlikely that prospective, head-to-head clinical fracture trials will be conducted due to the large number of patients required to show a difference between two effective therapies,' said Professor Delmas. 'Large, comparative, retrospective analyses, like the REAL study, are one way to fill the knowledge gap and should be considered in the total body of evidence for a drug to optimise treatment decisions and enhance patient care.'

Currently 1.6 million hip fractures occur worldwide per year, accounting for approximately €104 billion in worldwide annual healthcare costs. Among those patients who suffer a hip fracture, approximately one in five will die within the following year and 40% will be unable to walk independently one year later.

Source-Eurekalert
SRI
'"/>




Related medicine news :

1. First head-to-head trials of once weekly Fosamax and Actonel therapies
2. Cyclosporin A Treats Leukemia Complications
3. Weight Reduction Surgery Also Treats Metabolic Syndrome
4. Chennai Hospital Treats Pakistani Blue Baby
5. Cocoa Treats: Chocolates, as a Health Investment? Chew on this!
6. New Gene Therapy Treats Diabetic Neuropathy
7. BBIC – A SOY-based Substance Treats Multiple Sclerosi
8. Cake Walk – Plum Treats Sell Like Hot Cakes During Christma
9. Common BP Drug Treats Muscular Dystrophy
10. Naltrexone also Treats Crohns Disease
11. Drug for Blood Pressure also Treats Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/25/2017)... ... 2017 , ... Order Custom Tee Shirts Online , Welldonedesigns.com ... to be concerned about garment selection, expensive graphic designers, substandard printing, and shipping. ... and shipped within 5-10 days. And every garment we ship is shipped ...
(Date:9/25/2017)... ... September 25, 2017 , ... How many things are on your average ... phrase “more than any sane human could possibly complete,” then you’re all too familiar ... are desperately trying to be everything to everybody all the time. , Self-proclaimed overly ...
(Date:9/25/2017)... Grants Pass, OR (PRWEB) , ... September 25, ... ... good idea. Kleyne, host of the nationally syndicated The Sharon Kleyne Hour Power ... Tears® EyeMist®, would like us to shift our Olympic focus from a once-every-four-years ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... services supporting clinical research, today announces that 30 of its domain experts ... drug development lifecycle at upcoming industry conferences and webinars. Drawing on broad ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... to announce the next generation for LASIK in Manhattan with Contoura Vision, the ... technologically advanced laser systems available in the United States to correct nearsightedness and ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
(Date:9/9/2017)... Lilly and Company (NYSE: LLY ) will ... an investigational, oral, first-in-class molecule for the acute treatment ... placebo in the Phase 3 SPARTAN study. Detailed results ... the International Headache Society (IHC) in Vancouver ... lasmiditan,s potential to reduce pain and provide freedom from ...
(Date:9/7/2017)... , Sept. 7, 2017  Zimmer Biomet Holdings, Inc. ... healthcare, today announced that it will be participating in ... Conference at the Grand Hyatt hotel in New York.  ... at 11:40 a.m. Eastern Time. A live ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com .   ...
Breaking Medicine Technology: